Almost One-Third of Women of Childbearing Age Fill Prescriptions for Opioid Painkillers
January 27th, 2015
Almost one-third of women of childbearing age had an opioid painkiller prescription filled each year from 2008 to 2012, according to a new government study. These drugs can increase the risk for birth defects, The New York Times reports.
The study, by the Centers for Disease Control and Prevention (CDC), found 39 percent of women ages 15 to 44 on Medicaid, and 28 percent of women of the same age group with private insurance, filled an opioid prescription in a pharmacy each of those years.
“These are dangerous drugs that are addictive, and we are substantially overusing them,” said CDC Director Dr. Thomas Frieden. He noted that women often do not know they are pregnant in the early weeks of a pregnancy, which is a crucial time for organ formation. If they take opioid painkillers, they could be “unknowingly exposing their unborn child,” he said.
Opioid painkiller exposure can raise the risk for defects in a baby’s brain, spine, heart and abdominal wall, the article notes. Babies whose mothers take opioids during pregnancy are also at risk of neonatal abstinence syndrome. A baby with the syndrome experiences symptoms of withdrawal from medications or drugs taken by a mother during pregnancy.
The researchers said it is not known why women on Medicaid had higher prescription rates than women with private insurance. “The higher opioid prescribing rates among Medicaid enrollees might be due to differences in the prescription medications covered under their health insurance plan, differences in use of health care services, or differences in the prevalence of underlying health conditions among Medicaid enrollees compared with persons covered by private health insurance,” the CDC noted in a news release.
Oxycodone, hydrocodone and codeine were the most frequently prescribed opioids for women with either public or private insurance.
The FDA recently voted in favor of pushing a new formulation of oxycodone hydrochloride for approval. The new OxyContin formula is more difficult to crush or dissolve which will hopefully make it harder to be used as a drug of abuse . The FDA recommended that Purdue Pharma's application for a new, resin-coated formulation should replace the original version, which has been on the market since 1996. Randall Flick, MD, an anesthesiologist at the Mayo Clinic who voted to recommend approval of the drug said, "Clearly the old formulation is worse than the new, although I think the difference is relatively small," Flick concluded, "Hardcore abusers are likely to devise new ways to break down the harder tablet or figure out which solvents will dissolve it fastest, within 'day or weeks' of the product's release on the market."